Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Humanised dinutuximab - St. Jude Children's Research Hospital/United Therapeutics

Next Previous
Drug Profile

Humanised dinutuximab - St. Jude Children's Research Hospital/United Therapeutics

Alternative Names: Hu14.18; hu14.18K322A; Humanised anti-GD2 antibody - United Therapeutics Corporation

Latest Information Update: 15 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator St. Jude Childrens Research Hospital
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neuroblastoma
  • No development reported Ewing's sarcoma; Malignant melanoma; Osteosarcoma

Most Recent Events

  • 09 Apr 2024 Renaissance Pharma Ltd. has been acquired and merged into Essential Pharma
  • 02 Aug 2023 St. Jude Children's Research Hospital enters into an agreement with Renaissance Pharma for the treatment of newly diagnosed high-risk neuroblastoma using humanised dinutuximab
  • 02 Aug 2023 Efficacy data from a phase II trial in Neuroblastoma released by Renaissance Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top